Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Ciba-Geigy
gptkb:Searle_Pharmaceuticals |
| gptkbp:activities |
partial agonist of dopamine D2 receptors
partial agonist of serotonin 5-H T1 A receptors |
| gptkbp:antagonist |
serotonin 5-H T2 A receptors
|
| gptkbp:approves |
gptkb:2002
gptkb:FDA |
| gptkbp:brand |
gptkb:Abilify
|
| gptkbp:clinical_trial |
Phase IV
Phase III |
| gptkbp:contraindication |
severe renal impairment
severe liver impairment hypersensitivity to aripiprazole |
| gptkbp:developed_by |
gptkb:Bristol-Myers_Squibb
gptkb:Otsuka_Pharmaceutical |
| gptkbp:dosage_form |
gptkb:software_framework
gptkb:tablet injectable |
| gptkbp:excretion |
urine
feces |
| https://www.w3.org/2000/01/rdf-schema#label |
Aripiprazole
|
| gptkbp:indication |
agitation associated with bipolar disorder
agitation associated with schizophrenia |
| gptkbp:ingredients |
C23 H27 Cl2 N3 O2
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P2 D6 inhibitors CY P3 A4 inhibitors |
| gptkbp:is_atype_of |
N05 A X12
|
| gptkbp:is_used_for |
schizophrenia
bipolar disorder autism spectrum disorder major depressive disorder |
| gptkbp:legal_issue |
prescription only
|
| gptkbp:lifespan |
75 hours
|
| gptkbp:manager |
oral
intramuscular |
| gptkbp:marketed_as |
gptkb:Abilify_Maintena
gptkb:Abilify_My_Cite gptkb:Aristada |
| gptkbp:metabolism |
liver
|
| gptkbp:research_areas |
mental health
pharmacology neuroscience psychiatry |
| gptkbp:side_effect |
anxiety
nausea drowsiness insomnia weight gain |
| gptkbp:type_of |
612143-67-9
|